false
0001173281
0001173281
2024-03-05
2024-03-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current
Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
March 5, 2024
NeuBase Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its
Charter)
| Delaware |
|
001-35963 |
|
46-5622433 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
| 350
Technology Drive, Pittsburgh,
PA |
|
15219 |
| (Address
of Principal Executive Offices) |
|
(Zip Code) |
| |
(412)
763-3350 |
|
| |
(Registrant’s
Telephone Number, Including Area Code) |
|
| |
N/A |
|
| |
(Former
Name or Former Address, if Changed Since
Last Report) |
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| Common
Stock, par value $0.0001 per share |
NBSE |
The
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR § 240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events.
As previously reported, on February
22, 2024, the board of directors (the “Board”) of NeuBase Therapeutics, Inc. (the “Company”) determined
that it is in the best interests of the Company’s stockholders for the Company to dissolve, liquidate and distribute to stockholders
its available assets. The Company has been engaged in an evaluation of potential strategic or other alternatives in order to preserve
and maximize stockholder value, including an acquisition, merger, business combination, dissolution or other transaction.
On March 5,
2024, the Board unanimously approved the plan of liquidation and dissolution of the Company (the “Plan of Dissolution”) in
respect of the Company’s liquidation and dissolution, subject to the approval of the Company’s stockholders. The Company
plans to hold a special meeting of stockholders (the “Special Meeting”) at a time, date and location to be announced
to seek approval of the liquidation and dissolution of the Company and the Plan of Dissolution and
will file proxy materials relating to the Special Meeting with the Securities and Exchange Commission (the “SEC”). The Board
reserves the right to abandon the proposed liquidation and dissolution and the Plan of Dissolution, even if approved by the Company’s
stockholders, if the Board, in its discretion, determines that the liquidation and dissolution of the Company or the Plan of Dissolution
is no longer in the best interests of the Company and its stockholders.
A copy of the Plan of Dissolution is filed as Exhibit 2.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
IMPORTANT ADDITIONAL INFORMATION AND WHERE
TO FIND IT
In connection with the proposed liquidation
and dissolution and the Plan of Dissolution, the Company intends to file a proxy statement and other relevant materials with the
SEC. The definitive proxy statement will be sent to the Company's stockholders and will contain important information about the planned
dissolution. INVESTORS AND STOCKHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS
FILED WITH THE SEC WHEN THEY BECOME AVAILABLE. Investors and stockholders may obtain a free copy of the proxy statement (when it is available)
and other documents filed with the SEC at the SEC's website at www.sec.gov.
Participants in the Solicitation
The
Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders of
the Company in connection with the proposed liquidation and dissolution, the Plan
of Dissolution and related matters. Information about the persons who may be considered to
be participants in the solicitation of the Company's stockholders in connection with its planned dissolution, and any interest they have
in the proposed liquidation and dissolution, the Plan of Dissolution and related
matters, will be set forth in the definitive proxy statement when it is filed with the SEC. Further
information about the Company’s directors and executive officers is set forth in its proxy statement for its 2023 Annual Meeting
of Stockholders filed with the SEC on August 11, 2023. These documents may be obtained for free at the SEC's website at www.sec.gov.
Forward Looking Statements
Certain statements in this report constitute “forward-looking
statements” of the Company within the meaning of applicable laws and regulations and constitute “forward-looking information”
within the meaning of applicable securities laws. Any statements contained herein which do not describe historical facts, including
statements regarding the proposed liquidation and dissolution, Plan of Dissolution and the
related Special Meeting are forward-looking statements which involve risks and uncertainties that could cause actual results to differ
materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the possibility
that the Company’s stockholders will not realize any value in the Company’s shares or that the Plan of Dissolution will not
be able to be completed in a timely manner, or at all, as well as those risks identified in the Company’s filings with the SEC,
including under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year-ended September
30, 2022, and subsequent filings, with the SEC, available on the SEC’s website at www.sec.gov. Any such risks and uncertainties
could materially and adversely affect the Company’s results of operations and cash flows and the amount of time the Company can
meet its operational and capital needs. The Company cautions investors not to place undue reliance on any forward-looking statements,
which speak only as of the date they are made. Except as required by law, the Company undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
NEUBASE THERAPEUTICS, INC. (Registrant) |
| |
|
| Date: March 7, 2024 |
By: |
/s/ Todd P. Branning |
| |
|
Todd P. Branning |
| |
|
Chief Executive Officer and Chief Financial Officer |
| |
|
(Principal Executive, Financial and Accounting Officer) |
Exhibit 2.1
PLAN
OF LIQUIDATION AND DISSOLUTION
OF
NEUBASE THERAPEUTICS, INC.
This Plan of Liquidation
and Dissolution (the “Plan”) is intended to accomplish the complete liquidation and dissolution of NEUBASE THERAPEUTICS,
INC., a Delaware corporation (such corporation or a successor entity, the “Company”), in accordance with Section 281(b) of
the General Corporation Law of the State of Delaware (the “DGCL”).
1. Approval and Adoption of the Dissolution and the Plan. The Board of Directors of the Company (the “Board”)
has approved the dissolution of the Company pursuant to Section 275 of the DGCL (the “Dissolution”). The Board (i)
has determined that it is advisable and in the best interests of the Company and its stockholders that the Company be dissolved pursuant
to this Plan; (ii) approved this Plan by unanimous written consent; and (iii) called a special meeting
(the “Meeting”) of the holders of the Company’s common stock, par value $0.0001 per share (the “Common
Stock”), to approve the Dissolution and adopt this Plan by the affirmative vote of a majority of the outstanding shares of Common
Stock on the record date fixed by the Board (the “Requisite Consent”).
2.
Certificate of Dissolution. Subject to Section 15 hereof, following receipt of the Requisite Consent, an authorized
officer of the Company shall, unless the Board abandons the Dissolution in accordance with Section 275(e) of the DGCL, execute and file
with the Secretary of State of the State of Delaware a certificate of dissolution (the “Certificate of Dissolution”)
in accordance with the DGCL and the Dissolution shall be effective at such time as determined by the Board in its sole discretion (the
time of such filing, or such later time as stated therein, the “Effective Time”).
3.
Plan of Distribution. In accordance with Section 281(b) of the DGCL, before the third anniversary of the Effective Time
or such later time as may be ordered by the Court of Chancery pursuant to Section 278 of the DGCL, the Board shall approve and adopt a
plan of distribution to govern the liquidation and dissolution of the Company.
4.
Cessation of Business Activities. After the Effective Time, the Company shall not engage in any business activities except
to the extent necessary to preserve the value of its assets, wind up its business affairs and distribute its assets in accordance with
the Plan and the DGCL.
5.
Continuing Employees and Consultants. For the purpose of effecting the Dissolution, the Company may hire or retain such
employees, consultants and advisors as the Company deems necessary or desirable to supervise or facilitate the Dissolution, including
the process of winding up of the Company.
6.
Dissolution Process. After the Effective Time:
(a) The Company shall (i) pay or make reasonable provision to pay all claims and obligations (“Current Claims”),
including all contingent, conditional or unmatured contractual claims known to the Company (“Contingent Claims”), (ii) make
such provision as will be reasonably likely to be sufficient to provide compensation for any claim against the Company that is the subject
of a pending action, suit or proceeding to which the Company is a party (“Pending Action Claims”), and (iii) make such
provision as will be reasonably likely to be sufficient to provide compensation for claims that have not been made known to the Company
or that have not arisen but that, based on facts known to the Company, are likely to arise or to become known to the Company within 10
years after the Effective Time (“Potential Claims”, together with the Current Claims, Contingent Claims and Pending
Action Claims, the “Claims”). All Claims shall be paid in full and any such provision for payment made shall be made
in full if there are sufficient assets. If there are insufficient assets, the Claims shall be paid or provided for according to their
priority and, among claims of equal priority, ratably to the extent of assets legally available therefor.
(b)
After the payments of Claims are made pursuant to Section 6(a) herein, any remaining assets of the Company (the “Remaining
Assets”) shall be distributed to the stockholders of the Company in accordance with the Company’s Certificate of Incorporation
(as amended and/or restated through the Effective Time, the “Certificate of Incorporation”). Remaining Assets include,
but are not limited to, all available cash, including the cash proceeds of any sale, exchange or disposition, other than such cash, property
or assets as are required for paying or making reasonable provision for the Claims. Distributions in accordance with this Section 6(b)
may occur in a single distribution or in a series of distributions and shall be in cash or assets, in such amounts, and at such time or
times, as the Board in its absolute discretion, and in accordance with Sections 278 and 281 of the DGCL, may determine. If and to the
extent deemed necessary, appropriate or desirable by the Board, in its absolute discretion, the Company may establish and set aside a
reasonable amount of cash and/or property to satisfy claims against the Company, including, without limitation, tax obligations, all expenses
related to the sale of the Company’s property and assets, all expenses related to the collection and defense of the Company’s
property and assets, and the Dissolution and winding up provided for in the Plan.
Notwithstanding anything contained herein to the
contrary, the Company, at the discretion of the Board, may opt to dissolve and wind up the Company in accordance with the procedures set
forth in Sections 280 and 281(a) of the DGCL.
7.
Cancellation of Stock and Stock Certificates. From and after the Effective Time, and subject to applicable law, all holders
of any outstanding shares of capital stock of the Company shall cease to have any rights in respect thereof, except the right to receive
distributions, if any, pursuant to and in accordance with Section 6 hereof. As a condition to receipt of any distribution to the
Company’s stockholders, the Company may require the Company’s stockholders to (a) surrender their certificates evidencing
their shares of capital stock to the Company, or (b) furnish the Company with evidence satisfactory to the Company of the loss,
theft or destruction of such certificates, together with a surety bond or other security or indemnity as may be required by and satisfactory
to the Company. At the Effective Time, the Company will close its stock transfer books and discontinue recording transfers of shares of
capital stock of the Company, and thereafter any certificate representing shares of capital stock of the Company will not be assignable
or transferable on the books of the Company except by will, intestate succession, operation of law or upon the dissolution of the stockholders
or their successors.
8.
Continuation of the Company. The Company shall continue, for the term of three (3) years from the Effective Time or for
such longer period as the Court of Chancery shall in its discretion direct, as a body corporate for the purpose of prosecuting and defending
suits, whether civil, criminal or administrative, by or against it, and of enabling it gradually to settle and close its business, to
dispose of and convey its property, to discharge its liabilities and to distribute to its stockholders any Remaining Assets, but not for
the purpose of continuing the business for which the Company was organized. With respect to any action, suit or proceeding begun by or
against the Company either prior to or within three (3) years after the Effective Time, the action shall not abate by reason of the Dissolution;
the Company shall, solely for the purpose of such action, suit or proceeding, be continued as a body corporate beyond the three (3) year
period and until any judgments, orders or decrees therein shall be fully executed, without the necessity for any special direction to
that effect by the Court of Chancery. The powers of the officers and directors of the Company shall continue during this time period in
order to allow them to take the necessary steps to wind up the affairs of the Company.
9.
Absence of Appraisal Rights. Under Delaware law, the Company’s stockholders are not entitled to appraisal rights for
shares of capital stock of the Company in connection with the transactions contemplated by the Plan.
10.
Abandoned Property. If any distribution to a stockholder of the Company cannot be completed in accordance with Sections
6 and 7 hereof prior to the Company’s final liquidating distribution, the proceeds of the distribution to which such stockholder
is entitled shall be transferred to the official of such state or other jurisdiction authorized by applicable law to receive the proceeds
of such distribution. The proceeds of any such distribution shall thereafter be held solely for the benefit of and for ultimate distribution
to such stockholder, who shall constitute the sole equitable owner thereof, and the proceeds of any such distribution shall be treated
as abandoned property and escheat to the applicable state or other jurisdiction in accordance with applicable law. In no event shall the
proceeds of any such distribution revert to or become the property of the Company.
11.
Stockholder Consent to Sale of Assets. The approval of the Dissolution and the approval and adoption of this Plan by the
Requisite Consent shall constitute the approval of the stockholders of the Company of the sale, exchange or other disposition in liquidation
of all of the property and assets of the Company, whether such sale, exchange or other disposition occurs in one transaction or a series
of transactions, and shall constitute ratification of all contracts for sale, exchange or other disposition that are conditioned on adoption
of this Plan. The Company shall not be required to obtain appraisals, fairness, or other third-party opinions in connection with the valuation
of its properties and assets in connection with the implementation of this Plan.
12.
Expenses of Dissolution. In connection with and for the purposes of implementing and assuring completion of this Plan, the
Company may, in the sole and absolute discretion of the Board, pay any brokerage, agency, professional and other fees and expenses of
persons rendering services to the Company in connection with the collection, sale, exchange or other disposition of the Company’s
property and assets and the implementation of this Plan.
13.
Compensation. In connection with and for the purpose of implementing and assuring the completion of this Plan, the Company
may pay the Company’s officers, directors, employees, agents and representatives, or any of them, compensation or additional compensation
above their regular compensation, including pursuant to severance and retention agreements, in money or other property, in recognition
of the extraordinary efforts they, or any of them, will be required to undertake, or actually undertake, in connection with the implementation
of this Plan. Adoption of this Plan by the Requisite Consent shall constitute, to the fullest extent permitted by law, the approval of
the Company’s stockholders of the payment of any such compensation.
14.
Indemnification. The Company shall continue to indemnify and provide for advancement of expenses to its officers, directors,
employees, agents and trustees in accordance with the Certificate of Incorporation and the bylaws of the Company (as amended and/or restated
through the Effective Time), any contractual arrangements, and any existing directors’ and officers’ liability insurance policy,
including regarding acts or omissions of such persons in connection with the Dissolution and the implementation of the Plan. The Company
is authorized to obtain and maintain insurance as may be necessary, appropriate or desirable to cover the Company’s indemnification
obligations.
15.
Modification, Amendment or Abandonment. Notwithstanding obtaining the Requisite Consent to the Plan, the Board may modify,
amend or abandon the Plan and the transactions contemplated hereby without further action by the stockholders of the Company to the extent
permitted by the DGCL.
16.
Internal Revenue Service Filings. Within thirty (30) days after the Requisite Consent is obtained, the Company shall file
Form 966 with the appropriate Internal Revenue Service Center, together with a certified copy of the resolutions adopting this Plan. Additionally,
the Company shall file such additional forms and reports with the Internal Revenue Service as may be necessary or appropriate in connection
with this Plan and the carrying out thereof.
17.
Authorization. The Board is hereby authorized, without further action by the stockholders of the Company, to do and perform
or cause the officers of the Company to do and perform, any and all acts, and to make, execute, deliver or adopt any and all agreements,
resolutions, conveyances, certificates and other documents of every kind that are deemed necessary, appropriate or desirable, to implement
this Plan and the transactions contemplated hereby, including, without limiting the foregoing, all filings or acts required by any state
or federal law or regulation to wind up the affairs of the Company.
v3.24.0.1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Oct 2024 to Nov 2024
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Nov 2023 to Nov 2024
